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ABSTRACT
Objective We sought to evaluate COVID-19 clinical 
course in patients with IBD treated with different 
medication classes and combinations.
Design Surveillance Epidemiology of Coronavirus Under 
Research Exclusion for Inflammatory Bowel Disease 
(SECURE- IBD) is a large, international registry created 
to monitor outcomes of IBD patients with confirmed 
COVID-19. We used multivariable regression with a 
generalised estimating equation accounting for country 
as a random effect to analyse the association of different 
medication classes with severe COVID-19, defined as 
intensive care unit admission, ventilator use and/or 
death.
Results 1439 cases from 47 countries were included 
(mean age 44.1 years, 51.4% men) of whom 112 
patients (7.8%) had severe COVID-19. Compared with 
tumour necrosis factor (TNF) antagonist monotherapy, 
thiopurine monotherapy (adjusted OR (aOR) 4.08, 95% 
CI 1.73 to 9.61) and combination therapy with TNF 
antagonist and thiopurine (aOR 4.01, 95% CI 1.65 to 
9.78) were associated with an increased risk of severe 
COVID-19. Any mesalamine/sulfasalazine compared 
with no mesalamine/sulfasalazine use was associated 
with an increased risk (aOR 1.70, 95% CI 1.26 to 2.29). 
This risk estimate increased when using TNF antagonist 
monotherapy as a reference group (aOR 3.52, 95% CI 
1.93 to 6.45). Interleukin-12/23 and integrin antagonists 
were not associated with significantly different risk than 
TNF antagonist monotherapy (aOR 0.98, 95% CI 0.12 to 
8.06 and aOR 2.42, 95% CI 0.59 to 9.96, respectively).
Conclusion Combination therapy and thiopurines may 
be associated with an increased risk of severe COVID-19. 
No significant differences were observed when 
comparing classes of biologicals. These findings warrant 
confirmation in large population- based cohorts.
MKH should be changed to MDK for co- last author line
INTRODUCTION
COVID-19, caused by SARS- CoV-2, was first 
reported in December 2019 and has rapidly spread 
throughout the world leading to an international 
pandemic.1 Although most cases of COVID-19 are 
mild, the disease can become severe and result in 
hospitalisation, respiratory failure or death with 
reported case fatality rates ranging from 2.3% 
to 7.2%.2 3 The vast majority of patients with 
COVID-19 requiring hospitalisation or intensive 
care unit (ICU) admission have at least one comor-
bidity.4 Specific risk factors for severe COVID-19 
include increasing age, high fever, cardiovascular 
disease, diabetes, obesity, chronic obstructive 
pulmonary disease and chronic kidney disease.2 5–7
IBDs, including Crohn’s disease (CD) and UC, 
are chronic inflammatory conditions of the GI 
tract affecting millions of people worldwide.8–10 
Patients with IBD frequently require treatment with 
immunosuppressant medications that can increase 
Significance of this study
What is already known on this subject?
 ► Patients with IBD who are older, have
additional comorbidities and are on oral
corticosteroids appear to be at increased risk of
adverse outcomes from COVID-19.
 ► Prior data have suggested that patients with
IBD on mesalamine/sulfasalazine may be at
increased risk for severe COVID-19, while
patients on tumour necrosis factor (TNF)
antagonists do not appear to be at increased
risk.
What are the new findings?
 ► Based on data on over 1400 patients with IBD
from an international registry, compared with
TNF monotherapy, thiopurine monotherapy
and the combination thiopurines with TNF
antagonists are associated with significantly
increased risk of severe COVID-19.
 ► Mesalamine/sulfasalazine may be associated
with an increased the risk of severe COVID-19, 
particularly when compared with TNF
antagonists.
 ► There are no significant differences between
biological classes (TNF, interleukin-12/23 and
integrin antagonists) on the risk of severe
COVID-19.
How might it impact on clinical practice in the 
foreseeable future?
 ► These findings provide data to help clinicians
and patients with IBD make informed, shared
decisions about risks of medications in the
COVID-19 era.
the risk of serious viral and bacterial infections.11–14 However, 
it is also possible that immunosuppressive medications may be 
associated with a decreased risk of adverse COVID-19 outcomes 
by limiting the cytokine storm characteristic of severe COVID-
19.15 16
Using the Surveillance Epidemiology of Coronavirus 
Under Research Exclusion for Inflammatory Bowel Disease 
(SECURE- IBD) database, a large international registry of IBD 
patients with COVID-19, we previously reported that cortico-
steroids and mesalamine/sulfasalazine are associated with an 
increased risk of severe COVID-19, defined as requirement 
for ICU admission, ventilator support or death, while tumour 
necrosis factor (TNF) antagonists did not impact this risk.17 
However, the number of reported cases available at that time 
limited the ability to fully evaluate the risk of these and other 
IBD therapies. In this report, we sought to further evaluate the 
association of IBD medications and their combinations on the 
risk of adverse COVID-19 outcomes. In particular, we aimed to 
understand the impact of TNF antagonist monotherapy versus 
combination therapy with thiopurines as well as to further 




The SECURE- IBD database ( www. covidibd. org) was created to 
monitor outcomes of COVID-19 occurring in paediatric and 
adult patients with IBD. SECURE- IBD is an international, collab-
orative effort endorsed and promoted by numerous regional and 
national organisations as previously described.17 Physicians and 
other healthcare providers voluntarily reported cases of PCR- 
confirmed or antibody- confirmed COVID-19 occurring in IBD 
patients. We instructed healthcare providers to report cases, 
regardless of severity, after a minimum of 7 days from symptom 
onset and sufficient time had passed to observe the disease course 
through resolution of acute illness or death. In the event that a 
patient’s status changed after reporting or if there were concerns 
about data accuracy, we instructed reporters to rereport and 
contact the research team to remove their initial entry.
We used Research Electronic Data Capture (REDCap), a 
secure, web- based electronic data capture tool hosted at the 
University of North Carolina at Chapel Hill to collect and 
manage study data. Healthcare providers recorded the following 
information: age, country of residence, state of residence (if 
applicable), year of COVID-19 diagnosis, name of centre/
practice/physician providing care, sex, race, ethnicity, height, 
weight, patient’s diagnosis (CD, UC or IBD unclassified (IBD- 
U)), disease activity (as defined by physician global assessment 
(PGA)), medications at time of COVID-19 diagnosis, whether 
the patient was hospitalised, GI symptoms related to COVID-
19, COVID-19 treatments used and whether the patient died of 
COVID-19 or complications related to COVID-19. For hospital-
ised patients, the name of hospital, length of stay, need for ICU 
and need for mechanical ventilation were additionally recorded. 
For the current analyses, we used SECURE- IBD data collected 
from inception (13 March 2020) to 9 June 2020.
Quality control
We identified potential duplicate records by matching age, sex, 
IBD disease type, country and state (USA only) and reviewed 
these manually. Confirmed duplicates were excluded from anal-
ysis. Reports from non- valid email addresses were flagged as 
potential errors, and we performed a Google search of reporters 
and practice locations to confirm legitimacy of reports. Reporters 
were confirmed as being healthcare providers through a Google 
search of the reporter’s name and institution. If we could not 
confirm the reporter was a healthcare provider, reports from 
non- valid email addresses were excluded from analysis.
Statistical analysis
Continuous variables were summarised using means and SD and 
categorical variables using proportions. Our primary outcome 
was severe COVID-19, defined as a composite of ICU admis-
sion, mechanical ventilation and/or death, consistent with 
existing COVID-19 literature.18 Comorbidities were collapsed 
into the following categories: cardiovascular disease (coro-
nary artery disease, heart failure and/or arrhythmia), diabetes, 
hypertension, stroke, lung disease (asthma, chronic obstructive 
pulmonary disease and other lung disease), kidney disease, liver 
disease and cancer. Medication classes of interest at the time of 
COVID-19 infection included mesalamine/sulfasalazine, thiopu-
rine (mercaptopurine or azathioprine), systemic corticosteroids, 
TNF antagonists, interleukin (IL) 12/23 antagonists (usteki-
numab) and integrin antagonists (vedolizumab). Combination 
therapy was considered coprescription of a TNF antagonist with 
a thiopurine.
We first evaluated the impact of TNF antagonists and thio-
purines, either alone or in combination, on the risk of severe 
COVID-19. We compared any TNF antagonist use with no 
TNF antagonist use among all patients. Then, using an active 
comparator design, we compared thiopurine monotherapy and 
combination therapy with TNF antagonists to TNF antagonist 
monotherapy.19
We next undertook a series of analyses to further evaluate the 
association of mesalamine/sulfasalazine with severe COVID-19. 
We first compared any mesalamine/sulfasalazine use with no 
mesalamine/sulfasalazine use among all patients. Next, as TNF 
antagonists were the most frequently used medications among 
cases reported to SECURE- IBD, we compared patients treated 
with mesalamine/sulfasalazine without TNF antagonists (mesa-
lamine/sulfasalazine monotherapy) to those treated with TNF 
antagonists without mesalamine/sulfasalazine to those receiving 
both mesalamine/sulfasalazine and TNF antagonist biologi-
cals. We then compared outcomes among patients on mesala-
mine/sulfasalazine monotherapy to patients on no medications. 
Last, we compared patients treated with high versus low dose 
mesalamine/sulfasalazine, defined as ≥4 g daily of mesalamine 
(compared with <4 g daily) or >2 g daily of sulfasalazine 
(compared with ≤2 g daily).
To explore the effect of newer biologicals while maintaining 
an active comparator design, we compared IL-12/23 antago-
nist and integrin antagonist monotherapy to TNF antagonist 
monotherapy. As few patients treated with IL-12/23 and inte-
grin antagonists received concomitant thiopurines, only patients 
using monotherapy were included in these analyses.
We then analysed the impact of corticosteroid use versus no 
corticosteroid use on severe COVID-19 outcomes in this larger 
cohort from SECURE- IBD.
For all analyses, crude data on COVID-19 outcomes are 
provided for the overall study population and stratified by 
medication comparisons of interest. Bivariate comparisons 
were assessed using χ2 or Fisher’s exact tests as appropriate. 
For adjusted analyses, we performed multivariable regression 
modelling with a generalised estimating equation accounting 
for country as a random effect. The multivariable models a 
priori included age, sex, disease phenotype (CD or UC/IBD- U), 
corticosteroid use and cardiovascular disease as well as any other 
variables significant in univariable analysis at the p<0.05 level. 
Cardiovascular disease was included a priori as this has consis-
tently been one of the stronger comorbidities associated with 
adverse COVID-19 outcomes.20 21 One exception was the model 
examining integrin antagonists where a number of comorbidities 
were significant in univariable analyses so a single comorbidity 
variable was created with the number of comorbidities strati-
fied as 0, 1 or 2+. In addition, for sulfasalazine/mesalamine, we 
conducted exploratory analyses stratified by disease type (UC or 
CD only) and by age (<50 years or ≥50 years). For the primary 
comparisons of interest (impact of TNF antagonist monotherapy 
vs combination therapy with thiopurines and impact of mesala-
mine/sulfasalazine), we also adjusted p values for multiple testing 
using Bonferroni correction, dividing the level of significance 
(0.05) by the number of hypothesis tests (n=6) made. All data 
were prepared and analysed using SAS V.9.3 (SAS Institute, Cary, 
North Carolina, USA). Two- sided p values <0.05 were consid-
ered statistically significant.
Ethical considerations
Each SECURE- IBD survey item met criteria for deidentified 
data, in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA) Safe Harbor De- Identification stan-
dards. The UNC- Chapel Hill Office for Human Research Ethics 
has determined that the storage and analysis of deidentified data 
for this project does not constitute human subjects research as 
defined under federal regulations (45 CFR 46.102 and 21 CFR 
56.102) and does not require IRB approval.
Patient and public involvement
A number of patient and professional organisations have been 
engaged in study planning, promotion and results dissemination 
(online supplemental table 1).
RESULTS
A total of 1439 cases from 47 countries (online supplemental 
table 2) and 39 states within the USA were included. The mean 
age was 44.1 years (SD 17.6), 51.4% were men and 82.1% were 
white. The majority of patients had CD (55.2%), and over half 
(57.1%) were in remission by PGA at the time of COVID-19 
infection. Over a third of patients (37.2%) had at least one 
comorbidity in addition to IBD, the most common being hyper-
tension (13.7%), lung disease (9.3%) and cardiovascular disease 
(7.6%). The most frequently used medications were TNF antag-
onists (38.5%) and mesalamine/sulfasalazine (30.6%). Overall, 
112 patients (7.8%) experienced the primary outcome of severe 
COVID-19 with most being age 50 years or older (88/112, 
79%). Eighty- two patients (5.7%) were admitted to an ICU, 
66 (4.6%) required mechanical ventilation and 49 died (3.4%) 
due to COVID-19 or related complications. Ninety per cent of 
deaths (44/49) were in patients age 50 years or older.
We first evaluated the association of TNF antagonists with 
severe COVID-19. Patients on TNF antagonists were younger, 
more likely to have CD and be on concomitant thiopurine 
therapy, and less likely to be of Asian race, or have comorbidities 
compared with all other patients not on a TNF antagonist (online 
supplemental table 3). In unadjusted analyses, TNF antagonist 
users experienced lower rates of severe COVID-19 compared 
with non- users (1.1% vs 4.8%, p<0.001). However, on multi-
variable analysis, TNF antagonist therapy was not significantly 
associated with severe COVID-19 (adjusted OR (aOR) 0.69, 
95% CI 0.43 to 1.10).
We then compared TNF antagonist monotherapy with thiopu-
rine monotherapy and combination therapy. Among TNF antag-
onist users, 284 patients were on an intravenous TNF antagonist 
(infliximab) while 231 were on a subcutaneous medication 
(adalimumab, golimumab or certolizumab). Among all thiopu-
rine users, there were 220 on azathioprine and 40 on mercapto-
purine. On univariable analysis, compared with TNF antagonist 
monotherapy, thiopurine monotherapy patients had higher mean 
age and were more likely to be Asian race, be on concomitant 
sulfasalazine/mesalamine or corticosteroids and have cardiovas-
cular disease (table 1). Combination therapy patients, compared 
with TNF antagonist monotherapy, were more likely to be Asian 
race, be on concomitant sulfasalazine/mesalamine or corticoste-
roids and have cardiovascular disease. Patients on TNF antago-
nists (monotherapy or combination therapy) were more likely 
to have CD. Combination therapy and thiopurine monotherapy 
both had a significantly higher proportion of patients with severe 
COVID-19 compared with TNF antagonist monotherapy (8.8% 
and 9.2% vs 2.2%, respectively, p<0.001). On multivariable 
analysis, compared with TNF antagonist monotherapy, patients 
on combination therapy (aOR 4.01, 95% CI 1.65 to 9.78) and 
thiopurine monotherapy (aOR 4.08, 95% CI 1.73 to 9.61) had 
a significantly increased risk of severe COVID-19 (figure 1 and 
table 2). As multiple tests were performed that may increase the 
chance of type I error, we applied Bonferroni correction and the 
impact of combination and thiopurine monotherapy remained 
significant (table 2). A reduced model with variables selected 
using backward selection had similar findings to the full multi-
variable model (online supplemental table 4).
Next, we examined the association between mesalamine/
sulfasalazine with severe COVID-19. Mesalamine/sulfasalazine 
users, compared with non- users, had a higher mean age, were 
less likely to be black, more likely to be Asian or Hispanic, more 
likely to have UC, more likely to be on corticosteroids, less likely 
to be on biologicals and more likely to have other comorbidi-
ties including cardiovascular disease, diabetes, lung disease and 
cancer (table 3). Users of mesalamine/sulfasalazine had a signifi-
cantly higher proportion of patients with severe COVID-19 
compared with non- users (13.9% vs 5.2%, p<0.001). On multi-
variable analysis, any mesalamine/sulfasalazine use was associ-
ated with severe COVID-19 compared with no use (aOR 1.47, 
95% CI 1.05 to 2.07) (table 4). After applying the Bonferroni 
correction, associations of mesalamine/sulfasalazine remained 
significant (table 4).
Compared with users of TNF antagonist without mesalamine/
sulfasalazine, mesalamine/sulfasalazine users (monotherapy 
or in combination with TNF antagonists) had a higher mean 
age, were more likely to be Asian, have UC or be on concom-
itant corticosteroids and less likely to be in remission (online 
supplemental table 5). The mesalamine/sulfasalazine mono-
therapy group had a significantly higher proportion of patients 
with severe COVID-19 compared with TNF antagonist mono-
therapy (14.8% vs 3%, p<0.001). Patients on both mesalamine/
sulfasalazine and TNF antagonists concomitantly were also 
more likely to have severe COVID-19 compared with TNF 
antagonist monotherapy (9.3% vs 3%, p=0.008). In adjusted 
analyses, mesalamine/sulfasalazine monotherapy was associated 
with severe COVID-19 when compared with TNF antagonist 
monotherapy (aOR 3.52, 95% CI 1.93 to 6.45) (table 4). When 
comparing patients on concomitant mesalamine/sulfasalazine 
and TNF antagonists to TNF antagonist monotherapy, the effect 
size was attenuated and no longer statistically significant (aOR 
2.34, 95% CI 0.86 to 6.37). In sensitivity analyses, the increased 
risk of severe COVID-19 with mesalamine/sulfasalazine 
monotherapy, compared with TNF antagonist monotherapy, 
was still significant after stratifying by disease type (CD: aOR 
3.50, 95% CI 1.48 to 8.28; UC: aOR 5.74, 95% CI 1.15 to 
28.76). After stratifying by age, the effect of mesalamine/sulfas-
alazine monotherapy, compared with TNF antagonist mono-
therapy, remained significant in those age 50 years and older 
(aOR 3.15, 95% CI 1.31 to 7.60). In patients younger than 50 
years, the effect size was similar but not statistically significant 
(aOR 2.63, 95% CI 0.85 to 8.19). In an exploratory analysis, we 
compared users of only mesalamine/sulfasalazine to users of no 
medications and observed no significant association with severe 
COVID-19 (aOR 0.92, 95% CI 0.39 to 2.55). Lastly, we did 
not observe a difference in risk of severe COVID-19 comparing 
high and low dose mesalamine/sulfasalazine (aOR 0.99, 95% CI 
0.63 to 1.57).
When exploring comparisons between different classes of 
biologicals, patients on IL-12/23 antagonists, compared with 
those on TNF antagonists, were more likely to have CD and 
have any comorbidity and less likely to be on concomitant mesa-
lamine/sulfasalazine therapy (online supplemental table 6). In 
unadjusted and adjusted analyses, no significant difference in 
severe COVID-19 was noted when comparing patients treated 
with TNF versus IL-12/23 antagonists (online supplemental table 
7). Integrin antagonist patients had a higher mean age and were 
more likely to have UC and a number of comorbidities including 
diabetes, cancer, stroke and chronic liver disease compared 
with the TNF antagonist group (online supplemental table 8). 
In unadjusted analyses, integrin antagonist patients had a higher 
proportion with severe COVID-19 compared with those on 
TNF antagonists (7.2% vs 2.2%, p=0.007). After adjustment, 
this association was no longer statistically significant (aOR 2.42, 
95% CI 0.59 to 9.96).
Among all patients, after adjusting for age, sex, race (black 
vs non- Hispanic white, Asian vs non- Hispanic white), Hispanic 
versus non- Hispanic ethnicity, disease type, disease activity, 
cardiovascular disease, TNF antagonist, thiopurine, diabetes, 
lung disease and cancer, corticosteroid use was significantly asso-
ciated with severe COVID-19 (aOR 3.24, 95% CI 1.78 to 5.90).








Mean age, years (SD) 38.5 (16.2) 45.6 (16.0) <0.001 41.1 (15.0) 0.13
Female, n (%) 194 (47.3) 73 (47.1) 0.82 48 (45.7) 0.67
Race, n (%)
 White 338 (82.4) 133 (85.8) 0.34 89 (84.8) 0.57
 Asian 0.001 12 (8.8) <0.001 20 (12.9) 10 (2.4)
 Black 35 (8.5) 6 (3.9) 0.06 4 (3.8) 0.10
Ethnicity, n (%)
 Hispanic 63 (15.4) 34 (21.9) 0.05 23 (21.9) 0.05
CD, n (%) 292 (71.2) 78 (50.3) <0.001 66 (62.9) 0.06
UC/IBD- U, n (%) 118 (28.8) 77 (49.7) 39 (37.1)
Disease Aactivity, n (%)
 Remission 258 (62.9) 98 (63.3) 0.80 57 (54.3) 0.35
 Mild 69 (16.8) 30 (19.4) 17 (16.2)
 Moderate/Ssevere, n (%) 72 (17.6) 25 (16.1) 27 (25.7)
 Missing/Uunknown, n (%) 6 (1.5) 2 (1.2) 4 (3.8)
Current smoker, n (%) 16 (3.9) 5 (3.2) 0.70 6 (5.7) 0.41
Any comorbidity, n (%) 114 (27.8) 49 (31.6) 0.37 40 (38.1) 0.04
Cardiovascular Ddisease, n (%) 15 (3.7) 13 (8.4) 0.02 11 (10.5) 0.004
BMI ≥30 kg/m2, n (%) 62 (15.1) 23 (14.8) 0.79 25 (23.8) 0.10
Mesalamine/sulfasalazine, n (%) 43 (10.5) 61 (39.4) <0.001 27 (25.7) <0.001
Corticosteroid, n (%) 17 (4.1) 16 (10.3) 0.005 16 (15.2) <0.001
Severe COVID-19, n (%) 9 (2.2) 15 (9.7) <0.001 10 (9.5) <0.001
Death from COVID-19 or related complications, n (%) 3 (0.7) 3 (1.9) 0.36 3 (2.9) 0.17
*Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non- mutually exclusive variables.
†P value comparing thiopurine monotherapy with TNF antagonist monotherapy.
‡P value comparing combination therapy with TNF antagonist monotherapy.
BMI, body mass index; CD, Crohn’s disease; IBD- U, IBD unclassified; TNF, tumour necrosis factor.;
Figure 1 Proportion of patients with IBD with severe COVID-19 
and aORs comparing TNF antagonist monotherapy with thiopurine 
monotherapy and combination therapy. Model adjusted for age, sex, 
race (Asian vs non- Asian), disease type, disease activity, cardiovascular 
disease, corticosteroids and sulfasalazine/mesalamine. aOR, adjusted 
OR; TNF, tumour necrosis factor.
DISCUSSION
We investigated the impact of different medication classes on 
the risk of severe COVID-19 in patients with IBD using the 
SECURE- IBD registry. In over 1400 patients from this inter-
national database, we observed that patients on thiopurine 
monotherapy and combination therapy were at higher risk of 
a requiring ICU admission, mechanical ventilation and/or death 
compared with TNF antagonist monotherapy. Patients on mesa-
lamine/sulfasalazine appeared to have increased risk of severe 
COVID-19 as well, though these differences varied based on the 
reference group used. We did not observe any significant differ-
ences in COVID-19 outcomes when comparing classes of biolog-
icals including TNF, IL-12/23 and integrin antagonists.
Our results are largely consistent with the first analysis of 
SECURE- IBD data but add more granular data on the impact of 
IBD medications on severe COVID-19. We observed that thio-
purine monotherapy and combination therapy were both signifi-
cantly associated with severe COVID-19, compared with TNF 
antagonist monotherapy. The impact of combination therapy 
on increased COVID-19 disease severity appears to be driven 
primarily by thiopurines as the effect estimates for thiopurine 
monotherapy and combination therapy compared with TNF 
antagonist monotherapy were similar. This is in line with previous 
studies that have observed a higher risk of viral infections in 
patients treated with thiopurines alone or in combination with 
TNF antagonists.12 Our data suggest that COVID-19 should be 
Table 2 Unadjusted and adjusted analyses comparing the impact of TNF antagonist monotherapy with thiopurine monotherapy and combination 
therapy on risk of severe COVID-19
Medication comparison OR (95% CI) aOR (95% CI) P value* P value† Total n in model N with severe COVID-19
TNF antagonist
(ref=No TNF antagonist)‡
0.47 (0.29 to 0.62) 0.69 (0.43 to 1.10) 0.12 0.52 1415 111
Combination therapy 3.29 (1.31 to 8.25) 4.01 (1.65 to 9.78) 0.002 0.008 670 34
Thiopurine monotherapy
(ref=TNF antagonist monotherapy)§
3.15 (1.55 to 6.43) 4.08 (1.73 to 9.61) 0.001 0.013
*P value for adjusted model.
†Adjusted p value using Bonferroni correction method for six hypothesis tests that were conducted.
‡Model adjusted for age, sex, race (black vs non- Hispanic white, Asian vs non- Hispanic white), Hispanic versus non- Hispanic, disease type, disease activity, cardiovascular 
disease, corticosteroids, thiopurine, diabetes, lung disease and cancer.
§Model adjusted for age, sex, race (Asian vs non- Asian), disease type, disease activity, cardiovascular disease, corticosteroids and sulfasalazine/mesalamine.
aOR, adjusted OR; TNF, tumour necrosis factor.
Table 3 Demographics and clinical characteristics of COVID-19 IBD patients treated with mesalamines
Characteristic* 5- ASA/sulfasalazine (n=432) No 5- ASA/sulfasalazine (n=983) P value
Mean age, years (SD) 49.3 (18.4) 41.6 (16.7) <0.001
Female, n (%) 204 (47.2) 463 (47.1) 0.96
Race, n (%)
 White 367 (85) 796 (81) 0.16
 Asian 54 (12.5) 31 (3.2) <0.00
 Black 13 (3) 81 (8.2) <0.001
Ethnicity, n (%)
 Hispanic 90 (20.8) 155 (15.8) <0.0016
CD, n (%) 99 (23) 685 (69.7) <0.001
UC/IBD- U, n (%) 333 (77) 298 (30.3)
Disease activity, n (%)
 Remission 231 (53.5) 581 (59.1) 0.34
 Mild 86 (19.9) 168 (17.1)
 Moderate/severe, n (%) 99 (22.9) 199 (20.3)
 Missing/unknown, n (%) 16 (3.7) 35 (3.5)
Current smoker, n (%) 14 (3.2) 53 (5.4) 0.08
Any comorbidity, n (%) 189 (43.8) 337 (34.3) 0.001
Cardiovascular disease, n (%) 51 (11.8) 56 (5.7) <0.001
Diabetes, n (%) 36 (8.3) 46 (4.7) 0.01
Cancer, n (%) 17 (3.9) 16 (1.6) 0.01
Lung disease, n (%) 50 (11.6) 81 (8.2) 0.046
BMI ≥30 kg/m2, n (%) 69 (16) 166 (16.9) 0.74
Thiopurine, n (%) 88 (20.4) 188 (19.1) 0.59
TNF antagonist, n (%) 75 (17.4) 471 (47.9) <0.001
Corticosteroid, n (%) 45 (10.4) 65 (6.6) 0.01
Severe COVID-19, n (%) 60 (13.9) 51 (5.2) <0.001
Death from COVID-19 or related complications, n (%) 27 (6.3) 21 (2.1) <0.001
*Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non- mutually exclusive variables.
5- ASA, 5- aminosalycilates (mesalamine); BMI, body mass index; CD, Crohn’s disease; IBD- U, IBD unclassified; TNF, tumour necrosis factor.
added to the list of potential infectious complications associated 
with thiopurine therapy in IBD. Additionally, in select high- risk 
patients (ie, older age or multiple comorbidities) in stable remis-
sion on TNF antagonist combination therapy, consideration of 
discontinuing the thiopurine while the COVID-19 pandemic 
continues may be warranted.
In addition, most of our data suggest the possibility that TNF 
antagonist therapy may have a protective effect against the 
development of severe COVID-19 relative to other IBD ther-
apies. Higher baseline TNF levels have been associated with an 
increased risk of death in COVID-19, and the use of TNF antag-
onists as a COVID-19 treatment has been advocated by some 
experts in order to blunt the robust inflammatory response seen 
in severe disease.15 22 At least one clinical trial has been planned 
in China to investigate the use of adalimumab biosimilar as a 
COVID-19 treatment (ChiCTR2000030089).
While we did not observe any significant differences between 
biologicals (TNF, IL-12/23 and integrin antagonists), future 
studies with larger samples sizes are needed to confirm safety 
across all classes of biologicals. Interestingly, IL-12/23 antago-
nist therapy appears to have a similar effect on risk of severe 
COVID-19 as TNF antagonist therapy. This warrants further 
exploration in other disease states and in translational studies 
to understand if IL-12/23 related pathways are upregulated in 
COVID-19 infection.
Mesalamine and sulfasalazine appear to be associated with 
severe COVID-19 infection in many of our comparisons. Patients 
on any mesalamine or sulfasalazine had a higher risk of severe 
COVID-19 compared with those not on mesalamine or sulfasal-
azine. In an active comparator analysis, mesalamine/sulfasalazine 
monotherapy was significantly associated with severe COVID-19 
compared with TNF antagonist monotherapy. This association 
also held after restricting analyses to UC or CD only populations. 
After stratifying by age (age 50 years and older vs less than 50 
years), we observed similar results with mesalamine/sulfasalazine 
in multivariable models though the association reached statistical 
significance only in the older population, perhaps related to the 
small number of events in younger patients. The combination 
of mesalamine/sulfasalazine and TNF antagonist therapy had an 
intermediate effect relative to mesalamine/sulfasalazine mono-
therapy and TNF antagonist monotherapy with a non- significant 
trend towards increased risk of severe COVID-19.
Whether these associations reflect a harmful effect of mesa-
lamine/sulfasalazine, a protective effect of TNF antagonists, 
drug–drug interaction, residual or unmeasured confounding 
or a combination of factors is difficult to state with certainty. 
Patients treated with mesalamine/sulfasalazine monotherapy did 
not appear to be at increased risk of severe COVID-19 compared 
with patients on no medications, though patients with IBD on 
no medications are likely a heterogenous group (mild disease, 
postsurgery and so on) and not an ideal comparison population. 
Additionally, among users of TNF antagonists, use of mesala-
mine/sulfasalazine in combination with TNF antagonists was not 
associated with an increased risk of severe COVID-19 in adjusted 
analyses. Furthermore, we did not observe a dose–response asso-
ciation between mesalamine/sulfasalazine and severe COVID-
19, which is evidence against a biological effect of mesalamine/
sulfasalazine on risk of poor COVID-19 outcomes. For these 
reasons, and as mesalamine and sulfasalazine have not been 
previously associated with risk of other infections, we consider 
these findings to be hypothesis generating. A causal relationship 
should only be considered after replication in other studies and 
populations and with supporting evidence from mechanistic 
studies to determine biological plausibility.23 Alternatively, it is 
also possible that mesalamine and sulfasalazine do not increase 
the risk of severe COVID-19, but other IBD medications such 
as TNF antagonists and other biologicals confer relative protec-
tion in comparison. Observed associations of mesalamine/
sulfasalazine with increased incidence of severe COVID-19 
relative to TNF antagonists could also be a result of unadjusted 
confounding such as from differences in socioeconomic status or 
access to care, although in the USA differences in TNF antago-
nist therapy were not observed between patients with commer-
cial versus Medicaid insurance for low- income populations.24
Given that mesalamines are the cornerstone of therapy for 
mild to moderate UC, we do not advocate pre- emptively with-
holding these therapies during the COVID-19 pandemic.25 
However, these results potentially add further reason to avoid or 
de- escalate mesalamine therapy in clinical situations where they 
are of limited benefit including as CD treatment and after escala-
tion to biological therapy particularly in older patients for whom 
the baseline risk of severe COVID-19 is already increased.26–28
Finally, similar to the first SECURE- IBD report, we continue 
to observe an increased risk of severe COVID-19 in patients on 
corticosteroids. It is important to note that an ongoing clinical 
trial reported initial results that treatment of severe COVID-19 
with dexamethasone has mortality benefit (RECOVERY Trial, 
NCT04381936).29 The increased risk of severe COVID-19 with 
corticosteroid treatment seen in SECURE- IBD is likely not in 
conflict with these results and may reflect the impact of steroids 
based on stage of disease. Steroids at the time of infection, prior 
to onset of cytokine storm, may have deleterious effects on viral 
Table 4 Unadjusted and adjusted analyses of impact of mesalamine/sulfasalazine on risk of severe COVID-19
Dose comparison OR (95% CI) aOR (95% CI) P value* P value† Total n in model N with severe COVID-19
Mesalamine/sulfasalazine
(ref=no mesalamine/sulfasalazine)‡
2.43 (1.90 to 3.11) 1.70 (1.26 to 2.29) <0.001 <0.006 1415 111
Mesalamine/sulfasalazine monotherapy 4.51 (2.68 to 7.61) 3.52 (1.93 to 6.45) <0.001 <0.006 903 74
mesalamine/sulfasalazine and TNF antagonist
(ref=TNF antagonist monotherapy)§
2.79 (1.07 to 7.22) 2.34 (0.86 to 6.37) 0.10 0.455
High dose mesalamine/sulfasalazine
(ref=low dose)¶
1.07 (0.67 to 1.72) 0.99 (0.63 to 1.57) 0.99 1.00 410 56
*P value for adjusted model.
†Adjusted p value using Bonferroni correction method for six hypothesis tests that were conducted.
‡Model adjusted for age, sex, race (black vs non- Hispanic white, Asian vs non- Hispanic white), Hispanic versus non- Hispanic, disease type, disease activity, cardiovascular 
disease, corticosteroids, TNF antagonist, thiopurine, diabetes, lung disease and cancer.
§Model adjusted for age, sex, race (Asian vs non- Asian), disease type, disease activity, cardiovascular disease and corticosteroids.
¶Model adjusted for age, sex, race (white vs non- white), disease type, disease activity, cardiovascular disease, corticosteroids, combination therapy and thiopurine monotherapy.
aOR, adjusted OR; TNF, tumour necrosis factor.
clearance or immune response, whereas in severely ill patients, 
steroids may play a role in blunting a hyperimmune response.30
The strengths of this study include the robust, worldwide 
collaboration that enabled us to assemble clinical data on a large, 
geographically diverse sample of IBD patients and rapidly define 
the course of COVID-19 in this population. The reporting 
directly by physicians or their trained medical staff strengthens 
the validity of these data. Although our study sample is diverse 
in terms of age, geography, race and other factors, we acknowl-
edge several limitations and potential biases. SECURE- IBD is 
a convenience sample with many patients being from the USA 
and of white race and subsequently may not be fully representa-
tive of the worldwide IBD population. Given the observational 
nature of this cohort, there is the possibility of residual and/
or unmeasured confounding that could lead to altering effect 
estimates either away or towards the null. The reported results 
should only be interpreted as associations and causality cannot 
be inferred. In addition, as this was a registry- based cohort with 
convenience sampling, there is the possibility of reporting bias 
that could lead to over- representation or under- representation 
of more severe cases of COVID-19. For example, there may have 
been an over- reporting of patients with milder COVID-19 on 
intravenous medications as they may have more frequent contact 
with the healthcare system and therefore be more likely to have 
COVID-19 testing done. Additionally, the vast majority of severe 
COVID-19 events occurred in patients age 50 years or older, 
and therefore, the power and precision of the observed effect 
estimates may be limited for younger patients. This pattern is in 
line with the epidemiology of COVID-19 in the general popula-
tion in which older patients are at higher risk for severe disease. 
We were unable to evaluate methotrexate due to insufficient 
sample size. Similarly, limited numbers precluded meaningful 
analyses comparing sulfasalazine with mesalamine. Lastly, race 
was provided by the reporter using predefined racial categories 
based on US census categorisations. We acknowledge these cate-
gories may not be universally applicable in all jurisdictions in a 
multinational study such as this.
In conclusion, TNF antagonist combination therapy with thio-
purines and thiopurine monotherapy may be associated with a 
higher risk of severe COVID-19 in patients with IBD. As the 
majority of severe COVID-19 events occurred in patients over 
the age of 50 years, these data particularly highlight the risk of 
combination and thiopurine monotherapies in older patients 
with IBD. Our data also suggest that mesalamine/sulfasalazine 
therapy may be associated with severe COVID-19, but this asso-
ciation requires further replication in other populations. While 
our findings warrant replication in large population- based 
cohorts, these data can assist physicians and patients with IBD 
in shared clinical decision making during the era of COVID-19.
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